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Introduction {#sec001}
============

Andes virus (ANDV) is a rodent-borne hantavirus member of the *Bunyaviridae* family, and is unique for its ability to be transmitted from person-to-person \[[@pntd.0005757.ref001],[@pntd.0005757.ref002]\]. ANDV is endemic in Chile and according to the Chilean Ministry of Health (Department of Epidemiology, Chilean Ministry of Health; [http://www.minsal.cl](http://www.minsal.cl/)), 1087 cases of ANDV infection have been confirmed through May 2017 with a lethality rate of 35--40%. In humans, ANDV infection causes hantavirus cardiopulmonary syndrome (HCPS) \[[@pntd.0005757.ref003],[@pntd.0005757.ref004]\]. The initial symptoms of HCPS are non-specific and include fever, headache, and myalgia among others. However, in later phases, symptoms progress from coughing to severe pulmonary edema requiring intubation and mechanical ventilation, whilst cardiogenic shock is the main cause of death \[[@pntd.0005757.ref003],[@pntd.0005757.ref004]\]. Like other hantaviruses, the ANDV-induced illness is associated with the activation of the host\'s innate immune response, with cytokines playing a key role, rather than with direct cellular destruction induced by active virus replication \[[@pntd.0005757.ref005]\]. Currently, no FDA approved drugs, immunotherapeutics, or vaccines are available for HCPS prevention or treatment \[[@pntd.0005757.ref006]\]. Thus, patients' survival rates hinge largely on early diagnosis, hospital admission and aggressive pulmonary and hemodynamic support in an intensive care unit \[[@pntd.0005757.ref007],[@pntd.0005757.ref008]\]. Moreover, there are no blood biomarkers to predict the outcome of ANDV-induced HCPS. Interestingly, several reports show that the levels of the pro-inflammatory cytokines TNF-α, IL-1, IL-6, IL-10, and IFN-γ increase in patients infected with other hantaviruses such as Puumala Virus (PUUV), Dobrava Virus (DOBV), or the Sin Nombre Virus (SNV) \[[@pntd.0005757.ref005],[@pntd.0005757.ref009],[@pntd.0005757.ref010],[@pntd.0005757.ref011],[@pntd.0005757.ref012],[@pntd.0005757.ref013],[@pntd.0005757.ref014],[@pntd.0005757.ref015]\]. Additionally, high levels of IL-6 and TNF-α in plasma of SNV- and PUUV-infected patients is associated with a severe or fatal disease outcome \[[@pntd.0005757.ref005],[@pntd.0005757.ref010],[@pntd.0005757.ref013],[@pntd.0005757.ref014],[@pntd.0005757.ref016]\]. In the case of ANDV, elevated levels of cytokines including IL-6 were reported in ANDV-infected air-exposed organotypic human lung tissues \[[@pntd.0005757.ref017]\]. Motivated by these findings, we designed a study to evaluate the cytokine profile (IL-1β, IL-12p70, IL-21, TNF-α, IFN-γ, IL-10, IL-6) in serum samples of Chilean ANDV-infected patients collected at the time of hospitalization with the aim of establishing if the levels of any of the selected cytokines are linked to the severity of ANDV-induced disease. Cytokine selection was based on reports published for ANDV and other hantaviruses \[[@pntd.0005757.ref005],[@pntd.0005757.ref010],[@pntd.0005757.ref013],[@pntd.0005757.ref014],[@pntd.0005757.ref016]\]. Three cohorts were included; a group of healthy controls, a cohort of ANDV-infected patients with mild disease progression, and a cohort of ANDV-infected patients with a severe disease progression, many of whom subsequently died. Results show that on admission to hospital TNF-α, IFN-γ, IL-10, and IL-6 levels were elevated in serum of ANDV-infected patients compared to controls. Importantly, the serum levels of IL-6 in ANDV-infected patients at the time of hospitalization were associated with the severity of the clinical outcome of ANDV-induced disease.

Materials and methods {#sec002}
=====================

Study population {#sec003}
----------------

A total of 43 non-heat inactivated serum samples from ANDV-infected patients were selected based on their availability. Samples were obtained from a collection generated between January 2006 and January 2014 and stored at the Instituto de Salud Pública (ISP) de Chile or at the Laboratorio de Infectología, Facultad de Medicina, Pontificia Universidad Católica de Chile. These samples were collected for ANDV diagnosis at the time the patient was admitted to hospital, equivalent to 2--11 days after suspected ANDV infection (prodromic stage of the clinical course of HCPS). After collection, samples were stored at -8°C and not thawed more than once before use. In a previous study, the samples used had been catalogued as coming from patients with mild or severe symptoms, according to the severity of the final outcome of the ANDV-induced disease \[[@pntd.0005757.ref018]\]. Selected patients were non-related individuals and were considered to be representative of each group. Mild hantavirus infection was characterized by a febrile illness with unspecific symptoms such as headache, myalgias, chills, gastrointestinal symptoms, and no or minimal respiratory compromise \[[@pntd.0005757.ref018]\]. Severe cases exhibited rapid and progressive impaired lung function with the need for an external oxygen supply and the use of vasoactive drugs, resulting in shock and/or death \[[@pntd.0005757.ref018]\]. Based on this categorization, of the 43 infected samples used in this study, 21 were from mild casesand 22 were from severe cases. Fourteen individuals from the latter group subsequently died of HCPS, whilst there were no fatalities in the group showing mild symptoms. Approval for the use of the samples in this study was obtained from the Ethical Review Board of the Facultad de Medicina, Pontificia Universidad Católica de Chile (code 12--292 and 14--438). ANDV infection was confirmed by positive hantavirus immunoglobulin (IgM) serology or by ANDV genome detection by reverse transcription polymerase chain reaction (RT-PCR) \[[@pntd.0005757.ref018],[@pntd.0005757.ref019],[@pntd.0005757.ref020]\]. Control samples correspond to 43 non-heat treated serum samples obtained from healthy donors, who tested negative for ANDV, the human immunodeficiency virus, and hepatitis B and C virus infection.

Determination of cytokine levels in serum samples {#sec004}
-------------------------------------------------

Cytokines IL-1β, IL-12p70, IL-21, TNF-α, IFN-γ, IL-10 and IL-6 were measured in serum samples using a custom made Milliplex magnetic bead panel (Merck KGaA, Darmstadt, Germany) following the manufacturer's instructions. The lower limit of detection (pg/mL) for each cytokine in the assay was: IL-1β, 2.5; IL-12p70, 1.84; IL-21, 2.37; TNF- α, 1.23; IFN-γ, 4.95; IL-10, 4.5 and IL-6, 3.34.

Statistical analysis {#sec005}
--------------------

Results were analyzed using Graph Prism V6.0 (La Jolla, CA, USA) and Statistical Package for the Social Sciences (SPSS) V10.1 (SPSS, Inc., Chicago, IL, USA) software. The significance between the clinical and laboratory findings variables, and the clinical outcome was calculated by a Fisher\`s exact test. The relationship between the clinical outcome and the cytokine levels was determined by a Mann-Whitney test for continuous variables using only two variables in each analysis. The crude odd ratio (OR) values were calculated by a univariate logistic regression analysis followed by a multivariate stepwise forward and reverse logistic regression analysis using SPSS V10.1 software package. P values of \<0.05 were considered as significant.

Results {#sec006}
=======

The general characteristics of the ANDV-infected patients included in the study are summarized in [Table 1](#pntd.0005757.t001){ref-type="table"}. The mean age of the patients was 33 ± 14 years and 60.5% were male ([Table 1](#pntd.0005757.t001){ref-type="table"}). The vast majority of patients (97.7%) were infected between 32° 02' and 56° 30' south latitude (in the center and south of Chile) in rural areas (92.5%), consistent with the geographical distribution of the known viral reservoir in the long-tailed pygmy rice rat (*Oligoryzomys longicaudatus*) \[[@pntd.0005757.ref021]\]. The main clinical features and laboratory findings of the ANDV-infected patients, at the time of their admission in a hospital care unit are summarized in [Table 2](#pntd.0005757.t002){ref-type="table"}. In a previous study, samples of ANDV-infected patients used in this study had been grouped into mild or severe cases depending on the final clinical outcome of the disease \[[@pntd.0005757.ref018]\] ([Table 1](#pntd.0005757.t001){ref-type="table"}). A univariante analysis revealed that respiratory distress and haematocrit levels at the time of sample collection were significantly higher in patients that ultimately exhibited a severe clinical outcome ([Table 2](#pntd.0005757.t002){ref-type="table"}).

10.1371/journal.pntd.0005757.t001

###### Characteristic of andes virus-infected patients (n = 43).

![](pntd.0005757.t001){#pntd.0005757.t001g}

  Variable                                                            Patients, No. (%)
  ------------------------------------------------------------------- -------------------
  **Sex**                                                             
  Male \[n (%)\]                                                      26 (60.5)
  Female \[n (%)\]                                                    17 (39.5)
  **Age (mean, ± SD)**                                                33 ±14
  0--15 \[n (%)\]                                                     3 (7.0)
  16--30 \[n (%)\]                                                    15 (34.9)
  31--50 \[n (%)\]                                                    19 (44.1)
  51--80 \[n (%)\]                                                    6 (14.0)
  **Area (South latitude)**                                           
  North (17º30' to 32º16') \[n (%)\]                                  1 (2.3)
  Center (32º02'to 36º33') \[n (%)\]                                  8 (18.6)
  South (36º00' to 56º30') \[n (%)\]                                  34 (79.1)
  Area of infection \[n (%)\][^a^](#t001fn002){ref-type="table-fn"}   
  Urban area                                                          3 (7.5)
  Rural area                                                          37 (92.5)
  **Outcome**                                                         
  Mild \[n (%)\]                                                      21 (48.8)
  Severe \[n (%)\][^b^](#t001fn003){ref-type="table-fn"}              22 (51.2)
  Total Lethality \[n (%)\]                                           14 (32.5)

Abbreviation: SD, Standard deviation.

^a^ 40 patients with available data.

^b^ Including the 14 deceased patients.

10.1371/journal.pntd.0005757.t002

###### Available clinical and laboratory findings at the time of sample collection.

![](pntd.0005757.t002){#pntd.0005757.t002g}

  Variable                                                               Patients, No. (%)                                P value     
  ---------------------------------------------------------------------- ------------------------------------------------ ----------- --------------
  **Fever (\>38.5°C)**                                                   22 (100.0)                                       19 (90.5)   0.2326
  **Gastrointestinal symptoms**                                          16 (72.7)                                        16 (76.2)   0.5360
  **Headache**                                                           20 (90.9)                                        18 (85.7)   0.4771
  **Myalgia**                                                            18 (81.8)                                        18 (85.7)   0.5274
  **Respiratory distress**                                               22 (100.0)                                       12 (57.1)   \*\*\*0.0005
  **Infiltrates on chest X-ray**                                         19 (86.4)                                        15 (71.4)   0.2043
  **Blood shift (\>10% bands)**                                          6 (27.3)                                         2 (9.5)     0.1350
  **Atypical lymphocytosis**[^**b**^](#t002fn002){ref-type="table-fn"}   2 (10.5)[^c^](#t002fn003){ref-type="table-fn"}   1 (4.8)     0.4615
  **Thrombocytopenia**[^**d**^](#t002fn004){ref-type="table-fn"}         19 (86.4)                                        19 (90.5)   0.5229
  **Increased hematocrit**[^**e**^](#t002fn005){ref-type="table-fn"}     12 (54.5)                                        5 (23.8)    \*0.0394

^a^ Classified according to clinical outcome.

^b^ Defined as \>10% atypical lymphocytes.

^c^ Available data for 19 severe patients.

^d^ Defined as \< 150.000 mm^3^.

^e^ Defined as \>52% for men and \>48% for women.

Cytokine levels in serum of healthy controls and ANDV-infected patients {#sec007}
-----------------------------------------------------------------------

The levels of pro-inflammatory cytokines in serum samples of healthy controls and ANDV-infected patients were determined using a custom designed Th17 based Bead-Based Multiplex assay coupled with a Luminex platform. The results obtained for IL-1β, IL-12p70, IL-21, TNF-α, IFN-γ, IL-10, and IL-6 in each group are shown in Figs [1](#pntd.0005757.g001){ref-type="fig"} and [2](#pntd.0005757.g002){ref-type="fig"}, whilst the mean concentration (pg/mL) of each cytokine is shown in [Table 3](#pntd.0005757.t003){ref-type="table"}. When compared to the group of non-infected controls, no significant differences in IL-1β concentration were observed in ANDV-infected patients (mild plus severe patients; p = 0.9672), when comparing the control group with each individual sub-group (mild p: 0.5916; severe p = 0.6549), or between those suffering mild or severe symptoms (p = 0.4759) ([Fig 1A](#pntd.0005757.g001){ref-type="fig"} and [Table 3](#pntd.0005757.t003){ref-type="table"}). The levels of IL-12p70 and IL-21 were significantly lower in ANDV-infected patients when compared to the controls (p = \<0.0001), although no differences in the levels of IL-12p70 (p = 0.4119) and IL-21 (p = 0.9084) were detected between those showing mild and severe symptoms ([Fig 1B and 1C](#pntd.0005757.g001){ref-type="fig"}, and [Table 3](#pntd.0005757.t003){ref-type="table"}). The expression of TNF-α ([Fig 2A](#pntd.0005757.g002){ref-type="fig"}), IFN-γ ([Fig 2B](#pntd.0005757.g002){ref-type="fig"}), IL-10 ([Fig 2C](#pntd.0005757.g002){ref-type="fig"}), and IL-6 ([Fig 2D](#pntd.0005757.g002){ref-type="fig"}) exhibited higher levels in ANDV-infected individuals than in the non-infected control group, and levels were not affected by disease severity in the case of TNF-α, IFN-γ, and IL-10 ([Fig 2A--2C](#pntd.0005757.g002){ref-type="fig"} and [Table 3](#pntd.0005757.t003){ref-type="table"}). Notably however, the severe group of ANDV-infected patients displayed significantly more IL-6 compared to those with milder disease symptoms (2.1 log~10~, fold increase of 40.4; p \<0.0001) ([Fig 2D](#pntd.0005757.g002){ref-type="fig"} and [Table 3](#pntd.0005757.t003){ref-type="table"}). Due to the evident overlap in the levels of IL-6 when patients are categorized as mild or severe, it may be that reliance on IL-6 to determine a \"severe\" outcome for a patient is inadequate. To address this issue, the 43 patients were grouped according to their real final status, as either survivors or fatalities ([Fig 3](#pntd.0005757.g003){ref-type="fig"} and [Table 4](#pntd.0005757.t004){ref-type="table"}). For this, the eight severe patients who survived were grouped with the 21 mild individuals (none of whom died), and these 29 patients were then compared with the 14 severe and fatal cases of ANDV infection. The results show that the serum concentration of IL-6 was significantly higher in the fatal cases compared to the surviving (2.0 log~10~, fold increase of 28.3; p \<0.0001) or the control group (3.2 log~10~, fold increase 150.8; p \<0.0001) ([Fig 3](#pntd.0005757.g003){ref-type="fig"} and [Table 4](#pntd.0005757.t004){ref-type="table"}).

![IL-1β, IL-12p70, and IL-21 levels in control and ANDV-infected patients.\
Circulating levels of cytokines (A) IL-1β, (B) IL-12p70 and (C) IL-21 in serum samples of Control individuals and ANDV-infected patients with Mild or Severe disease progression are represented by dots. IL-1β and IL-12p70 were expressed in pg/mL while the circulating levels of IL-21 are expressed as Log~10~ (pg/mL) to facilitate comparison between the groups. A Mann-Whitney test for continuous variables was performed to evaluate significant differences between Controls and Mild or Severe, and Severe versus Mild groups. The ends of the brackets indicate the compared groups. The dashed line represents the lower limit of detection. Each serum sample was analyzed in duplicate in the same plate.](pntd.0005757.g001){#pntd.0005757.g001}

![TNF-α, IFN-γ, IL-10, and IL-6 levels in control and ANDV-infected patients.\
Circulating levels of cytokines (A) TNF-α, (B) IFN-γ, (C) IL-10, and (D) IL-6 in serum samples of Control individuals and ANDV-infected patients with Mild or Severe disease progression are represented by dots. Each value expressed in pg/mL was transformed to Log~10~ (pg/mL) to facilitate comparison between the groups. A Mann-Whitney test for continuous variables was performed to evaluate significant differences between Controls and Mild or Severe, and Severe versus Mild groups. The dashed line represents the lower limit of detection. The ends of the brackets indicate the compared groups. Each serum sample was analyzed in duplicate in the same plate.](pntd.0005757.g002){#pntd.0005757.g002}

![Serum levels of IL-6 in control, HCPS survivals or fatal cases.\
Circulating levels of IL-6 in serum samples of control individuals and HCPS survivors or fatalities are represented by dots. Values are expressed in Log~10~ (pg/mL). A Mann-Whitney test for continuous variables was performed to evaluate significant differences between controls individuals and HCPS survivors or fatalities. The ends of the brackets indicate the compared groups. The dashed line represents the lower limit of detection. Each serum sample was analyzed in duplicate in the same plate.](pntd.0005757.g003){#pntd.0005757.g003}

10.1371/journal.pntd.0005757.t003

###### Cytokine concentration in serum of controls and ANDV-infected patients.

![](pntd.0005757.t003){#pntd.0005757.t003g}

  ---------------------------------------------------------------------------------------------------------------------
  \              \                           ANDV-Infected Patients\                           
  Cytokine       Controls\                   \[mean (min-max) pg/mL\]                          
                 \[mean (min-max) pg/mL\]\                                                     
                 (n = 43)                                                                      
  -------------- --------------------------- -------------------------- ---------------------- ------------------------
  **IL-1β**      3.49 (2.5--33.94)           4.60 (2.5--64.62)          3.84 (2.5--26.06)      5.32 (2.5--64.62)

  **IL-12p70**   21.86 (1.84--104.31)        5.43 (1.84--51.26)         7.28 (1.84--51.26)     3.67 (1.84--27.88)

  **IL-21**      74.23 (2.37--303.0)         16.75 (2.37--186.5)        21.57 (2.37--186.5)    12.14 (2.37--119.5)

  **TNF-α**      21.55 (2.90--85.35)         70.05 (15.87--407)         61.01 (17.18--144.5)   78.68 (15.87--407)

  **IFN-**γ      31.38 (4.95--183.0)         69.62 (4.95--652.0)        50.21 (4.95--183.0)    88.13 (5.99--652.0)

  **IL-10**      5.74 (4.5--45.49)           133.21 (4.5--776.0)        129.85 (4.5--776.0)    136.25 (4.5--347.0)

  **IL-6**       7.84 (3.34--105.64)         411.94 (3.34--10281.8)     19.47 (3.34--75.66)    786.57 (3.34--10281.8)
  ---------------------------------------------------------------------------------------------------------------------

^a^ Classified according to clinical outcome.

10.1371/journal.pntd.0005757.t004

###### Cytokine concentration in serum of survivors or deceased ANDV-infected patients.

![](pntd.0005757.t004){#pntd.0005757.t004g}

  ----------------------------------------------------------------------------------------------------------------
  \              ANDV-Infected Patients\                                                       
  Cytokine       \[mean (min-max) pg/mL\]                                                      
  -------------- -------------------------- ---------------------- --------------------------- -------------------
  **IL-1β**      4.60 (2.5--64.62)          3.48 (2.5--26.06)      6.94 (2.5--64.62)           \>0.9999

  **IL-12p70**   5.43 (1.84--51.26)         5.96 (1.84--51.26)     4.35 (1.84--27.88)          0.7508

  **IL-21**      16.75 (2.37--186.5)        17.36 (2.37--186.5)    15.48 (2.37--119.5)         0.5314

  **TNF-α**      70.05 (15.87--407)         61.75 (17.18--144.5)   87.26 (15.87--407)          0.6521

  **IFN-γ**      69.62 (4.95--652.0)        81.85 (4.95--652)      44.27 (5.99--93.57)         0.8880

  **IL-10**      133.21 (4.5--776.0)        128.40 (4.5--776.0)    143.22 (4.5--347.0)         0.3618

  **IL-6**       411.94 (3.34--10281.8)     41.59 (3.34--285)      1179.08 (13.075--10281.8)   \*\*\*\* \<0.0001
  ----------------------------------------------------------------------------------------------------------------

^a^ Classified according to clinical outcome.

Risk factor analysis by using a logistic regression model {#sec008}
---------------------------------------------------------

To control the potential confounding effects of the various risk factors identified by the univariate analysis, a multiple logistic regression model was constructed using the outcome and symptom severity of ANDV-infection, as the response variables. The stepwise forward and reverse logistic regression analysis included clinical variables (fever, gastrointestinal symptoms, headache, myalgia, respiratory distress, infiltrates on chest x-ray, blood shift, atypical lymphocytosis, thrombocytopenia, increased hematocrit) and the cytokine profiles. All cytokine values were dichotomized (above or under mean values). [Table 5](#pntd.0005757.t005){ref-type="table"} summarizes the crude odd ratios (OR) for each variable processed by a univariate logistic regression model, and the OR obtained by a multivariate stepwise forward (model 1) and reverse (model 2) logistic regression analysis. In model 1, respiratory distress (p = 0.9999) and IL-6 (p = 0.0130) are the only variables that affect HCPS outcome. In model 2, respiratory distress (p = 0.9999), increased hematocrit (p = 0.0670), and IL-6 (p = 0.0150) impact on HCPS outcome. However, for both models, only the difference between the levels of IL-6 in mild and severe ANDV-infected patients is significant, with OR values greater than 1.

10.1371/journal.pntd.0005757.t005

###### Logistic regression of clinical and cytokine level variables.

![](pntd.0005757.t005){#pntd.0005757.t005g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \                                                                 \          \           OR~model\ 1~\                     \           OR~model\ 2~\                                           \
  Variable                                                          crude OR   CI~or~      (IL-6 and respiratory distress)   CI~or~      (IL-6, respiratory distress and increased hematocrit)   CI~or~
  ----------------------------------------------------------------- ---------- ----------- --------------------------------- ----------- ------------------------------------------------------- -----------
  **Fever [^a^](#t005fn001){ref-type="table-fn"}**                  1.0        \-                                                                                                                

  **Gastrointestinal symptoms**                                     1.2        0.3--4.7                                                                                                          

  **Headache**                                                      0.6        0.1--4.1                                                                                                          

  **Myalgia**                                                       1.3        0.3--6.8                                                                                                          

  **Respiratory distress [^a^](#t005fn001){ref-type="table-fn"}**   1.0        \-          1.0                               \-          1.0                                                     \-

  **Infiltrate on chest X-Ray**                                     0.4        0.1--1.8                                                                                                          

  **Blood shift**                                                   0.3        0.1--1.6                                                                                                          

  **Atypical lymphocytosis**                                        2.2        0.2--26                                                                                                           

  **Thrombocytopenia**                                              1.5        0.2--10                                                                                                           

  **Increased hematocrit**[\*](#t005fn002){ref-type="table-fn"}     3.8        1--14.2                                                   6.9                                                     0.8--54.9

  **IL-1β**                                                         0.4        0.4--5.4                                                                                                          

  **IL-12p70**                                                      0.3        0.3--3.0                                                                                                          

  **IL-21**                                                         0.5        0.1--2.4                                                                                                          

  **TNF-α**                                                         1.6        0.5--5.7                                                                                                          

  **IFN-γ**                                                         1.4        0.4--4.8                                                                                                          

  **IL-10**                                                         2.0        0.6--6.9                                                                                                          

  **IL-6**[\*](#t005fn002){ref-type="table-fn"}                     14.4       3.3--63.1   10                                1.6--74.7   10.9                                                    1.6--74.7
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ OR not calculated because one or more boxes contain zero.

~\*~ Significant

OR model 1: Stepwise Forward

OR model 2: Stepwise Reverse

In summary, the results from this study show that IL-6 serum concentration at the time of patient hospitalization is linked to the severity of the disease induced by ANDV.

Discussion {#sec009}
==========

A growing number of reports suggest that the hosts' immune response plays a key role in hantavirus induced disease \[[@pntd.0005757.ref005],[@pntd.0005757.ref009],[@pntd.0005757.ref010],[@pntd.0005757.ref011],[@pntd.0005757.ref012],[@pntd.0005757.ref013],[@pntd.0005757.ref014],[@pntd.0005757.ref015],[@pntd.0005757.ref022]\]. Studies indicate that immune dysregulation rather than virus replication is responsible for the increasing changes in vascular permeability associated with HCPS \[[@pntd.0005757.ref023],[@pntd.0005757.ref024]\]. Upon hantavirus infection, the pathogens-associated molecular patterns (PAMPs) are recognized by the extracellular or intracellular receptors of endothelial host cells, leading to the local production of pro-inflammatory cytokines and chemokines, such as IL-1β, TNF-α, and IL-6, by activated macrophages \[[@pntd.0005757.ref010],[@pntd.0005757.ref025],[@pntd.0005757.ref026]\]. Additionally, Th1 cells produce IFN-γ and TGF-β, cytokines that are responsible for cell-mediated immunity, regulated by IL-12 \[[@pntd.0005757.ref010],[@pntd.0005757.ref027]\]. The regulatory T cells that produce the immunosuppressive cytokines IL-10 and TGF-β play an important role in the regulation of the immune response and limit the immunopathology induced by hantavirus infection \[[@pntd.0005757.ref010]\]. Thus, we were interested in determining whether the levels of serum cytokines in patients at the time of their admission to hospital were associated with the final clinical outcome of the ANDV-induced disease. To do so, we compared the levels of serum cytokines in three distinct groups of individuals: non-infected individuals (healthy controls), ANDV-infected patients with a mild disease progression and ANDV-infected patients with a severe disease progression.

When studying IL-1β we found that the serum levels of this cytokine remain unaltered in ANDV-infected patients when compared to that of the non-infected controls ([Fig 1A](#pntd.0005757.g001){ref-type="fig"}). This finding confirms previous reports showing no increase in the levels of IL-1β in patients infected with PUUV or in patients with HCPS \[[@pntd.0005757.ref005]\]. Nonetheless, other studies show that the cells producing IL-1β and other pro-inflammatory cytokines are concentrated in the lung tissue of individuals with HCPS \[[@pntd.0005757.ref026],[@pntd.0005757.ref028]\]. Therefore, these observations suggest that production of local cytokines in the lungs of ANDV-infected patients could differ from circulating levels of cytokines.

Results regarding the levels of IL-21 in hantavirus-infected individuals are dissimilar between previous reports \[[@pntd.0005757.ref005],[@pntd.0005757.ref029]\]. One study shows a high overexpression of IL-21 in patients with hemorrhagic fever with renal syndrome (HFRS) caused by hantavirus \[[@pntd.0005757.ref029]\]. In that study, the authors establish an association between the levels of IL-21 and the severity of HFRS. However, another study reports that there is no change in the levels of IL-21 in the serum of HCPS patients \[[@pntd.0005757.ref005]\]. In contrast to both previous studies \[[@pntd.0005757.ref005],[@pntd.0005757.ref029]\], our results show that in the group of ANDV-infected patients, IL-21 levels are significantly lower when compared to non-infected controls (p = \<0.0001) ([Fig 1C](#pntd.0005757.g001){ref-type="fig"}). It is worth noting that the pathology induced by New-World hantaviruses, HCPS, shares many, although not all of the clinical features of the disease caused by Old-World hantaviruses, HFRS. Thus, results obtained in the context of ANDV infection are not expected to fully match those that have been described for Old-World hantaviruses.

An interesting, yet expected finding, is that in ANDV-infected patients the serum levels of IL-12p70 are significantly lower (p = \<0.0001) when compared to the non-infected control group. This observation is in full agreement with a study showing a similar trend in Dobrava virus (DOBV) infected patients \[[@pntd.0005757.ref015]\]. A plausible explanation is to consider that the overexpression of a repressor cytokine, such as IL-10, would down regulate the levels of IL-12p70 \[[@pntd.0005757.ref030]\]. This possibility is strongly supported by our results, in which the level of IL-10 in serum of ANDV-infected patients is significantly higher (p = \<0.0001) than in the healthy controls ([Fig 2C](#pntd.0005757.g002){ref-type="fig"}; [Table 3](#pntd.0005757.t003){ref-type="table"}). It is well known that the overexpression of IL-10 is strongly favored by high levels of IL-6 and TNF-α \[[@pntd.0005757.ref015]\]. Additionally, overexpression of TNF-α and IL-6 are associated with inflammatory systemic disease, an increase in vascular permeability and with the production of a negative inotropic effect \[[@pntd.0005757.ref031],[@pntd.0005757.ref032]\]. In agreement with this positive loop of activation, our results show that the levels of IL-6 and TNF-α are elevated in ANDV-infected patients ([Fig 2A and 2D](#pntd.0005757.g002){ref-type="fig"}). In fact, when compared to non-infected controls, significant increases in the levels of TNF-α, IFN-γ, IL-10 and IL-6 in ANDV-infected patient are observed (p = \<0.0001; 0.0036; \<0.0001; \<0.0001, respectively) ([Fig 2A--2D](#pntd.0005757.g002){ref-type="fig"}). These findings are in full agreement with most previous studies \[[@pntd.0005757.ref005],[@pntd.0005757.ref010],[@pntd.0005757.ref014],[@pntd.0005757.ref015],[@pntd.0005757.ref033]\], although TNF-α expression is not always raised in patients with severe HCPS \[[@pntd.0005757.ref010]\]. This discrepancy cannot be readily explained; however, one possibility is to consider the genetic differences between the subjects included in these two studies, one conducted in Brazil \[[@pntd.0005757.ref010]\] and the other in Chile. Differences between both populations have been previously reported in other studies \[[@pntd.0005757.ref018],[@pntd.0005757.ref034]\].

Additionally, we compared TNF-α, IL-10, and IL-6 levels between mild and severe cases of ANDV-infection. Even though no significant differences in TNF-α or IL-10 levels exist between these two groups ([Fig 2A and 2C](#pntd.0005757.g002){ref-type="fig"}, and [Table 3](#pntd.0005757.t003){ref-type="table"}), the IL-6 levels in the serum of ANDV-infected patients with a mild disease progression increased by 2.49 fold (p = 0.0021) compared to the non-infected controls ([Fig 2D](#pntd.0005757.g002){ref-type="fig"}), whilst those with severe symptoms displayed a 100.7 fold (p = \<0.0001) increase in the levels of IL-6 compared to the control group ([Table 3](#pntd.0005757.t003){ref-type="table"} and [Fig 2D](#pntd.0005757.g002){ref-type="fig"}). Moreover, when categorizing patients into survivors and fatalities the IL-6 levels in fatal cases of ANDV infection were significantly higher compared to survivor or control patients ([Fig 3](#pntd.0005757.g003){ref-type="fig"} and [Table 4](#pntd.0005757.t004){ref-type="table"}). Finally, a multivariate stepwise forward and reverse logistic regression model was constructed, confirming the relevance of the IL-6 levels at the time of patient hospitalization in the prediction of the outcome of HCPS ([Table 5](#pntd.0005757.t005){ref-type="table"}). It is well documented that IL-6 levels are significantly elevated in the serum of patients with HCPS, epidemic nephropathy (EP), and HFRS \[[@pntd.0005757.ref005],[@pntd.0005757.ref012],[@pntd.0005757.ref035]\]. Consistent with our findings, other reports show that IL-6 levels are even higher in severe-disease patients compared with mild-disease patients \[[@pntd.0005757.ref013],[@pntd.0005757.ref035]\]. Thus, our findings establish a clear association between the Th1-type cytokine IL-6 and the severity of ANDV-induced HCPS, suggesting that the serum concentration of IL-6 at the time of hospitalization can potentially be used as a molecular marker to predict the clinical outcome in ANDV-infected patients, offering the promise of personalized intervention, right from the moment of hospital admission.
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